Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity –
Covered in this story
Analyst targets on Kura Oncology Inc
- Citizens JMP: $9.83 → $24 by Oct 2027 · Market Outperform via Investing.com
- UBS: $10.7 → $15 by Oct 2027 · Buy via Investing.com
- JPMorgan: $10.7 → $30 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kura Oncology Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.